Access
This article is part of Nature's premium content.
Published online 30 September 2008 |
Nature
| doi:10.1038/news.2008.1142
Updated online: 2 October 2008
Updated online: 7 October 2008
Column
A very public battle
The fight to buy ImClone highlights the value of new cancer drugs — especially if they're difficult to copy.
The ongoing struggle over New York-based biotechnology firm ImClone is about to take a new and perhaps decisive turn. Pharmaceutical company Bristol-Myers Squibb has been wooing the company ever more forcibly since July, but a mystery buyer has made a much better offer — and its identity may be revealed tomorrow.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
